Literature DB >> 8674235

Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus.

M Puurunen1, O Vaarala, H Julkunen, K Aho, T Palosuo.   

Abstract

There is accumulating evidence that anti-phospholipid (aPL) antibodies in the sera of patients with autoimmune diseases bind to a complex of anionic phospholipids and plasma phospholipid-binding proteins, namely beta 2-glycoprotein I (beta 2-GPI) and prothrombin. It has been suggested that a conformational change in beta 2-GPI, induced by binding either to anionic phospholipids or to the oxygen molecules on the irradiated microtiter plate, reveals cryptic antigenic epitope(s) in the native protein. We used an enzyme-linked immunoassay for measuring antibodies against two phospholipid-binding proteins, i.e., beta 2-GPI and prothrombin, absorbed to an irradiated plate in an unselected series of 139 patients with systemic lupus erythematosus (SLE). Elevated levels of antibodies against beta 2-GPI were found in 49% of patients and antibodies against prothrombin in 34% of patients. Both antibodies were significantly associated with deep venous thrombosis in patients with SLE (P = 0.009 for both antibodies). Accordingly, testing of these antibodies seems to be clinically useful in evaluating the risk of thrombosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674235     DOI: 10.1006/clin.1996.0089

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot.

Authors:  R R Forastiero; M E Martinuzzo; L O Carreras
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage.

Authors:  B Caronti; C Calderaro; C Alessandri; F Conti; R Tinghino; G Palladini; G Valesini
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals.

Authors:  P H Consigny; B Cauquelin; P Agnamey; E Comby; P Brasseur; J J Ballet; C Roussilhon
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  Specificity of anti-phospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies.

Authors:  M Sorice; V Pittoni; T Griggi; A Losardo; O Leri; M S Magno; R Misasi; G Valesini
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

5.  Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta2-glycoprotein I.

Authors:  C González; A Lestón; B García-Berrocal; A Sánchez-Rodriguez; J A Martín-Oterino; I Alberca; M Cordero; R Jorge; J A Navajo; J M González-Buitrago
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

6.  Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus.

Authors:  Ehtisham Akhter; Zakera Shums; Gary L Norman; Walter Binder; Hong Fang; Michelle Petri
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

7.  The thrombophilic network of autoantibodies in celiac disease.

Authors:  Aaron Lerner; Nancy Agmon-Levin; Yinon Shapira; Boris Gilburd; Sandra Reuter; Idit Lavi; Yehuda Shoenfeld
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

8.  Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease.

Authors:  S Loizou; S Singh; E Wypkema; R A Asherson
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 9.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.